Summary
This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Scope
Reasons to Buy
This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Scope
- The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio’s focus is on DNA-based vaccines requiring a novel route of administration
- Inovio’s pipeline is most active in early-stage drug development
- INO-4800 is Inovio’s COVID-19 vaccine
- Funding from different sources for INO-4800
Reasons to Buy
- An overview of how Inovio Pharmaceuticals Inc. will be affected by the COVID-19 pandemic.
Table of Contents
1 Executive Summary5 Key Findings
2 Company Overview
3 Regional Analysis
4 Reaction to COVID-19
6 Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Inovio Pharmaceuticals Inc.
